Link between Metabolic Syndrome and Insulin Resistance
Нема приказа
Аутори
Gluvić, ZoranZarić, Božidarka
Resanović, Ivana
Obradović, Milan M.
Mitrović, Aleksandar
Radak, Đorđe J.
Isenović, Esma R.
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Metabolic syndrome (MetS) is a leading public health and clinical challenge worldwide. MetS represents a group of interrelated risk factors that predict cardiovascular diseases (CVD) and diabetes mellitus (DM). Its prevalence ranges between 10 and 84%, depending on the geographic region, urban or rural environment, individual demographic characteristics of the population studied (sex, age, racial and ethnic origin), as well as the criteria used to define MetS. Persons with MetS have higher mortality rate when compared with people without MetS, primarily caused by progressive atherosclerosis, accelerated by pro-inflammatory and pro-coagulation components of MetS. Considering the high prevalence of metabolic disorders (glucose metabolism disorder, hypertension, dyslipidaemia, obesity etc.), preventive healthcare should focus on changing lifestyle in order to reduce obesity and increase physical activity. This narrative review considers the available evidence from clinical and experimenta...l studies dealing with MetS, and current treatment options for patients with insulin resistance and MetS.
Кључне речи:
Metabolic syndrome / insulin resistance / cardiovascular diseaseИзвор:
Current Vascular Pharmacology, 2017, 15, 1, 30-39Финансирање / пројекти:
- Хормонска регулација експресије и активности азот оксид синтазе и натријум-калијумове пумпе у експерименталним моделима инсулинске резистенције, дијабетеса и кардиоваскуларних поремећаја (RS-MESTD-Basic Research (BR or ON)-173033)
- Каротидна болест у Србији - патолошка динамика, превенција, дијагностика и иновативни терапијски поступци (RS-MESTD-Integrated and Interdisciplinary Research (IIR or III)-41002)
DOI: 10.2174/1570161114666161007164510
ISSN: 1570-1611; 1875-6212
PubMed: 27748199
WoS: 000397231200006
Scopus: 2-s2.0-85018402316
Колекције
Институција/група
VinčaTY - JOUR AU - Gluvić, Zoran AU - Zarić, Božidarka AU - Resanović, Ivana AU - Obradović, Milan M. AU - Mitrović, Aleksandar AU - Radak, Đorđe J. AU - Isenović, Esma R. PY - 2017 UR - https://vinar.vin.bg.ac.rs/handle/123456789/1470 AB - Metabolic syndrome (MetS) is a leading public health and clinical challenge worldwide. MetS represents a group of interrelated risk factors that predict cardiovascular diseases (CVD) and diabetes mellitus (DM). Its prevalence ranges between 10 and 84%, depending on the geographic region, urban or rural environment, individual demographic characteristics of the population studied (sex, age, racial and ethnic origin), as well as the criteria used to define MetS. Persons with MetS have higher mortality rate when compared with people without MetS, primarily caused by progressive atherosclerosis, accelerated by pro-inflammatory and pro-coagulation components of MetS. Considering the high prevalence of metabolic disorders (glucose metabolism disorder, hypertension, dyslipidaemia, obesity etc.), preventive healthcare should focus on changing lifestyle in order to reduce obesity and increase physical activity. This narrative review considers the available evidence from clinical and experimental studies dealing with MetS, and current treatment options for patients with insulin resistance and MetS. T2 - Current Vascular Pharmacology T1 - Link between Metabolic Syndrome and Insulin Resistance VL - 15 IS - 1 SP - 30 EP - 39 DO - 10.2174/1570161114666161007164510 ER -
@article{ author = "Gluvić, Zoran and Zarić, Božidarka and Resanović, Ivana and Obradović, Milan M. and Mitrović, Aleksandar and Radak, Đorđe J. and Isenović, Esma R.", year = "2017", abstract = "Metabolic syndrome (MetS) is a leading public health and clinical challenge worldwide. MetS represents a group of interrelated risk factors that predict cardiovascular diseases (CVD) and diabetes mellitus (DM). Its prevalence ranges between 10 and 84%, depending on the geographic region, urban or rural environment, individual demographic characteristics of the population studied (sex, age, racial and ethnic origin), as well as the criteria used to define MetS. Persons with MetS have higher mortality rate when compared with people without MetS, primarily caused by progressive atherosclerosis, accelerated by pro-inflammatory and pro-coagulation components of MetS. Considering the high prevalence of metabolic disorders (glucose metabolism disorder, hypertension, dyslipidaemia, obesity etc.), preventive healthcare should focus on changing lifestyle in order to reduce obesity and increase physical activity. This narrative review considers the available evidence from clinical and experimental studies dealing with MetS, and current treatment options for patients with insulin resistance and MetS.", journal = "Current Vascular Pharmacology", title = "Link between Metabolic Syndrome and Insulin Resistance", volume = "15", number = "1", pages = "30-39", doi = "10.2174/1570161114666161007164510" }
Gluvić, Z., Zarić, B., Resanović, I., Obradović, M. M., Mitrović, A., Radak, Đ. J.,& Isenović, E. R.. (2017). Link between Metabolic Syndrome and Insulin Resistance. in Current Vascular Pharmacology, 15(1), 30-39. https://doi.org/10.2174/1570161114666161007164510
Gluvić Z, Zarić B, Resanović I, Obradović MM, Mitrović A, Radak ĐJ, Isenović ER. Link between Metabolic Syndrome and Insulin Resistance. in Current Vascular Pharmacology. 2017;15(1):30-39. doi:10.2174/1570161114666161007164510 .
Gluvić, Zoran, Zarić, Božidarka, Resanović, Ivana, Obradović, Milan M., Mitrović, Aleksandar, Radak, Đorđe J., Isenović, Esma R., "Link between Metabolic Syndrome and Insulin Resistance" in Current Vascular Pharmacology, 15, no. 1 (2017):30-39, https://doi.org/10.2174/1570161114666161007164510 . .